Kelly Dooley, MD
Enriched profileDirector, Division of Infectious Diseases; Professor of Medicine and Addison B. Scoville Jr. Chair in Medicine (departing Vanderbilt for Brown University effective Sept 30, 2026, where she will become Chair of the Department of Medicine at Warren Alpert Medical School and Physician-in-Chief at Brown University Health) · Vanderbilt University Medical Center
Kelly Dooley is Director, Division of Infectious Diseases; Professor of Medicine and Addison B. Scoville Jr. Chair in Medicine (departing Vanderbilt for Brown University effective Sept 30, 2026, where she will become Chair of the Department of Medicine at Warren Alpert Medical School and Physician-in-Chief at Brown University Health) at Vanderbilt University Medical Center. OpenAlex indexes 230 publications with 9,519 citations (h-index 49); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Kelly Dooley, MD, is Director, Division of Infectious Diseases at Vanderbilt University Medical Center. The public record shows 230 publications with 9,519 citations (h-index 49), centered on Tuberculosis Research and Epidemiology, Pneumocystis jirovecii pneumonia detection and treatment, HIV/AIDS drug development and treatment. It also documents an investigator role on 13 registered clinical trials, 3 NIH-funded awards (2021–2025).
- Most recent indexed publication: 2026 · Clinical infectious diseases
- Top research focus: Tuberculosis Research and Epidemiology
- 13 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 131.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.vumc.org ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Short-course Regimens for the Treatment of Pulmonary Tuberculosis
Sponsor: Centers for Disease Control and Prevention
- Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB
Sponsor: University of KwaZulu
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%ACE inhibitor100%Lisinopril100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2021–2025 per NIH RePORTER. The latest:
- Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium
University of California, San Francisco
FY2026$7,200,000UM1AI179699 - Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) Consortium
University of California, San Francisco
FY2025$7,200,000UM1AI179699 - Short-course rifapentine for TB prevention for all: clinical pharmacology matters
Vanderbilt University Medical Center
FY2025$813,899R37AI184117
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Efficacy of isoniazid in paediatric tuberculosis: an individual participant data meta-analysis.
The European respiratory journal
Meta-analysis2026 - Pyrazinamide Safety, Efficacy, and Dosing for Treating Drug-Susceptible Pulmonary Tuberculosis: A Phase 3, Randomized Controlled Clinical Trial.
American journal of respiratory and critical care medicine
Clinical Trial2024
Most-cited works
by citation count (OpenAlex)- 01Tuberculosis and diabetes mellitus: convergence of two epidemics949 citations2009
- 02
- 04Tuberculous meningitis520 citations2017
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/kelly-dooley-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Spotify
asm.org/podcasts/editors-in-conversation/episodes/treatment-of-multidrug-resistant-tuberculosis-eic
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
- BA in Economics
Northwestern University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →news.vumc.org ↗ - Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗ - Board Certified
Infectious Diseases
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.vumc.org ↗
Editorial & leadership roles
journal and society appointments- Board of Directors
American Society for Clinical Pharmacology and Therapeutics (ASCPT), 3-year term beginning May 2025
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.vumc.org ↗ - Chair
TB Transformative Science Group, AIDS Clinical Trials Group (ACTG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →actgnetwork.org ↗ - Chair
CRUSH-TB trial, CDC Tuberculosis Trials Consortium
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →actgnetwork.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.vumc.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →treatmentactiongroup.org ↗
Secondary affiliations
appointments beyond the home institution- Professor of Pathology
Microbiology and Immunology, Vanderbilt University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vumc.org ↗ - Adjunct Professor of Medicine
Johns Hopkins University School of Medicine (ORCID-declared, current)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗ - Faculty affiliate
Vanderbilt Institute for Global Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →global-health.vmcweb.org ↗
Media & interviews
press, podcasts and appearances- Featured researcher
Vanderbilt Life Science Showcase (infectious disease research spotlight), July 2024
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.vanderbilt.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascpt.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nashvillepost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Wei Zheng, MD, PhD, MPH
Vanderbilt University Medical Center
Brian Rini, MD
Vanderbilt University Medical Center
William Schaffner, MD
Vanderbilt University Medical Center
Jordan Berlin, MD
Vanderbilt University Medical Center